



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 11, 2015

Via E-Mail

Mr. Sean Carrick  
President and Chief Executive Officer  
Nascent Biotech Inc.  
8400 Miramar Road  
Suite 247  
San Diego, California 92126

**Re: Nascent Biotech Inc.  
Form 10-12G  
Filed October 28, 2014  
File No. 000-55299**

Dear Mr. Carrick:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey Riedler  
Assistant Director

cc: Via E-Mail

Claudia J. McDowell, Esq.  
McDowell Odom LLP  
28494 Westinghouse Place, Suite 305  
Valencia, California 91355